Literature DB >> 20404218

Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction.

Arantxa González1, Begoña López, Ramón Querejeta, Elena Zubillaga, Tomás Echeverría, Javier Díez.   

Abstract

This study was designed to evaluate the association between circulating biomarkers of collagen metabolism and elevated left-sided filling pressures (FPs), as assessed from elevated estimated pulmonary capillary wedge pressure (ePCWP), in hypertensive patients with heart failure with normal ejection fraction. Echocardiography was performed and ePCWP was calculated from the formula ePCWP=1.90+1.24(maximum early transmitral flow velocity in diastole:tissue Doppler early mitral annulus velocity). The biomarkers of collagen synthesis (carboxy-terminal propeptide of procollagen type I) and degradation (matrix metalloproteinase [MMP] 1 and tissue inhibitor of MMP-1 [TIMP-1]) were analyzed by ELISA methods. Seventy-eight patients with normal FPs (ePCWP < or =15 mm Hg) and 78 with elevated FPs (ePCWP >15 mm Hg) were included. Compared with controls, the levels of the 3 biomarkers were increased in the 2 groups of patients. The MMP-1:TIMP-1 ratio, an index of MMP-1 activity, was increased in patients with normal FPs and unchanged in patients with elevated FPs. Patients with elevated FPs exhibited higher TIMP-1 levels and a lower MMP-1:TIMP-1 ratio than patients with normal FPs. ePCWP was independently associated with TIMP-1 (r=0.349; P<0.001) and the MMP-1:TIMP-1 ratio (r=-0.240; P<0.01) in all of the patients. Receiver operating characteristic curves showed that a cutoff value of TIMP-1 of 1557 ng/mL provided 64% sensitivity and 67% specificity for predicting elevated FPs with a relative risk of 3.71 (95% CI: 1.91 to 7.22). These findings suggest that, in hypertensive patients with heart failure with normal ejection fraction and elevated FPs, collagen synthesis predominates over degradation because of a relative excess of TIMP-1. This imbalance can facilitate myocardial fibrosis, which, in turn, may contribute to the elevation of FPs in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404218     DOI: 10.1161/HYPERTENSIONAHA.109.149112

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  34 in total

Review 1.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

Review 2.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

4.  Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension.

Authors:  Zeenat Safdar; Emilio Tamez; Wenyaw Chan; Basant Arya; Yimin Ge; Anita Deswal; Biykem Bozkurt; Adaani Frost; Mark Entman
Journal:  JACC Heart Fail       Date:  2014-07-09       Impact factor: 12.035

Review 5.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

6.  A change of heart: oxidative stress in governing muscle function?

Authors:  Martin Breitkreuz; Nazha Hamdani
Journal:  Biophys Rev       Date:  2015-06-27

Review 7.  Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications.

Authors:  William M Yarbrough; Rupak Mukherjee; John S Ikonomidis; Michael R Zile; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-16       Impact factor: 5.209

8.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

Review 9.  Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.

Authors:  Michael R Zile; Catalin F Baicu
Journal:  J Cardiovasc Transl Res       Date:  2013-05-29       Impact factor: 4.132

Review 10.  Heart failure with preserved ejection fraction: emerging drug strategies.

Authors:  Fouad A Zouein; Lisandra E de Castro Brás; Danielle V da Costa; Merry L Lindsey; Mazen Kurdi; George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.